Posts Tagged ‘Roche’

Yesterday Pfizer announced a $7.3 billion deal to buy Metsera, a company with an impressive obesity drugs portfolio. Roche, having spent $2.7 billion to acquire Carmot in 2023 and $1.6 billion in March on a deal with Zealand, yesterday confirmed its intent to spend everything it takes to become a market leader in obesity. “We […]

It’s been a rough month for investors in Lilly and Novo Nordisk – largely because of the prospects for rising competition to their wildly successful obesity medicines. Accelerating VK2735 This week, Viking Therapeutics announced they are accelerating development of injectable form of VK2735, a dual agonist that works on both GLP-1 and GIP receptors. This […]